Gullone v. Bayer Corp.
Opinion
MEMORANDUM OPINION
The basic issue presently before the court in this multidistrict litigation is whether we should grant the defendants’ motion to dismiss one of the constituent cases pursuant to the doctrine of forum non conveniens. The plaintiffs in the case of Gullone v. Bayer Corp., transferred here from the Northern District of California for pretrial proceedings, are six citizens and residents of Italy, one citizen and resident of Germany, and eight citizens and residents of the United Kingdom (“U.K.”). All of the plaintiffs in the MDL are persons who allege that they contracted either the HIV virus or the Hepatitis B virus by exposure, either directly or indirectly, to blood-clotting products manufactured by the four defendants for use by persons suffering from hemophilia. The plaintiffs are either hemophiliacs who allegedly used the products or spouses who allege infection as a result of the spousal relationship. The defendants are Bayer [571] Corporation, an Indiana corporation, Baxter Healthcare Corporation, a Delaware corporation, Armour Pharmaceutical Company, Inc., a Delaware corporation, and Alpha Therapeutic Corporation, a California corporation. Jurisdiction is based upon diversity of citizenship.
The Judicial Panel on Multidistrict Litigation has transferred a number of cases, including Gullone, to this district for pretrial proceedings. In addition, several similar cases have been filed in this district and are being treated as part of the multidistrict litigation.
The cases now pending are actually the “second generation” of this consolidated litigation and have been so labeled by the MDL Panel. The “first generation” cases were resolved some years ago, most of them by way of a class settlement of approximately 6000 claims.1
A discussion of the first generation claims is necessary to an analysis of the present forum non conveniens motion. For convenience, we will quote from one of our opinions regarding those earlier cases:
Plaintiffs in these consolidated cases are persons suffering from hemophilia, a hereditary disease in which the protein that causes blood clotting is missing. The principal treatment for the disease is the intravenous injection of the missing protein, derived from the plasma of blood donors. Four of the defendants are pharmaceutical companies which collect and process the plasma to derive “factor concentrates,” which are then sold for use by hemophiliacs. The manufacturing process for deriving the finished factor concentrate from blood plasma is known as “fractionating,” and the four defendants involved in the present dispute are known as “fractionators.”Footnotes
408 F. Supp. 2d 569 (Gullone v. Bayer Corp.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.